Beleodaq (belinostat) / Spectrum Pharma, Assertio, Valerio Therap, Aurobindo 
Welcome,         Profile    Billing    Logout  

16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beleodaq (belinostat) / Aurobindo, Assertio
2017-002561-21: Study of addition of belinostat to chemotherapy before surgery in patients with Thymic Epithelial Tumors (TET)

Ongoing
3
100
Europe
Belinostat, Powder for solution for infusion, Beleodaq (in the USA)
IFCT, Onxeo
Locally advanced potentially resectable Thymic Epithelial Tumors, Locally advanced Thymus Tumors, Diseases [C] - Cancer [C04]
 
 
NCT06561048: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Not yet recruiting
3
150
NA
Soquelitinib, CPI-818, Belinostat, Beleodaq®, Pralatrexate, Folotyn®
Corvus Pharmaceuticals, Inc.
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
02/26
09/27
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
NCT02137759: MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

Active, not recruiting
2
29
US
Standard Radiation Therapy, Standard Temozolomide, Temodar, Belinostat, Beleodaq, PXD101
Emory University, Johns Hopkins University, Spectrum Pharmaceuticals, Inc, National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Glioblastoma Multiforme of Brain
08/23
08/24
NCT02737046: Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Active, not recruiting
2
15
US
Belinostat, PXD101, Beleodaq®, Zidovudine, AZT, Interferon-Alfa-2b, IFN-α-2b, Pegylated Interferon-Alfa-2b, PEG-IFN-α-2b
University of Miami
Adult T-cell Leukemia-Lymphoma, ATLL
07/24
07/25
ETCTN, NCT04340843: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Active, not recruiting
2
32
US
Belinostat, Beleodaq, PXD 101, PXD-101, PXD101, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI 110, SGI-110, SGI110, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
01/25
01/25
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
2
50
US
Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar
University of Virginia, Celgene
PTCL
06/26
06/28
NCT06406465: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Not yet recruiting
2
60
US
Belinostat, Cisplatin, Etoposide
National Cancer Institute (NCI)
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma, Small Cell; Receptors
07/27
07/28
NCT05170334: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
Binimetinib, Mektovi, ARRY-162, Belinostat, Beleodaq
H. Lee Moffitt Cancer Center and Research Institute, Pfizer, Acrotech Biopharma Inc.
Metastatic Uveal Melanoma
12/24
12/24
NCT04184869: Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Completed
1
8
US
Belinostat, beleodaq, Atazanavir, Reyataz
Acrotech Biopharma Inc., Axis Clinicals Limited
Solid Tumor, Hematological Malignancies
12/22
03/23
NCT04703920: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Recruiting
1
25
US
Talazoparib, Belinostat
University of Michigan Rogel Cancer Center, Pfizer, Acrotech Biopharma Inc.
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma
12/24
12/24
ETCTN 10500, NCT05627245: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Suspended
1
64
US
Belinostat, Beleodaq, PXD 101, PXD-101, PXD101, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Positron Emission Tomography and Computed Tomography Scan, PET-CT Scan, PET/CT SCAN, Positron Emission Tomography/Computed Tomography, Tazemetostat, E 7438, E-7438, E7438, EPZ 6438, EPZ-6438, EPZ6438
National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
03/25
03/25
NCT03772925: Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Active, not recruiting
1
30
US
Belinostat, Beleodaq, PXD 101, PXD-101, PXD101, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924
National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
06/25
06/25
CHARGE, NCT04315233: Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

Recruiting
1
34
US
Ribociclib, Belinostat
University of Utah, Novartis, Acrotech Biopharma
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
08/24
08/26
RESOLVE, NCT05154994: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma

Suspended
1
9
US
Belinostat, Beleodaq, PXD 101, PXD101, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
University of Utah, National Cancer Institute (NCI)
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
11/24
11/26
NCT03432741: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Suspended
1
39
US
Belinostat, Beleodaq, PXD 101, PXD101, Carfilzomib, Kyprolis, PR-171, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera
Mayo Clinic, National Cancer Institute (NCI)
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
04/25
05/26

Download Options